GENEVA, Switzerland, September 3 /PRNewswire/ --
- Merck Serono Now Has Exclusive Worldwide Development and Commercialisation Rights to atacicept, Including in North America
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and ZymoGenetics, Inc. (NASDAQ: ZGEN), Seattle, United States, today announced a restructuring of their partnership.